Adverse Event (AE) Coding Data mining and cleaning Medical literature screening and report writing Cleaning juggled Drug- AE data and converting to machine.

Slides:

Advertisements

Similar presentations

The Information Professionals Role in Product Safety Jack Leitmeyer Director, Adverse Experience Information Management Worldwide Product Safety Merck.

Advertisements

Pharmacovigilance by Dr. Notghi Contract Research.

Common Terminology Criteria for Adverse Events (CTCAE) v.4: Updating a Cancer Research Standard Ann Setser 1, Ranjana Srivastava 2, Lawrence Wright 1,

5S CLÍNICA MÉDICA (MH) 306 A. 5S CLÍNICA MÉDICA (MH) 306 B.

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

FDA Perspective Sally Loewke, M.D. Acting Division Director

Code 2 Layers. Step 1 Using 2 Layers Step 2: There are 2 layers Using 2 Layers.

Knowledge Update Clinical documentation: from preclinical studies to drug registration Split, 12 September 2008.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Clinical Data Management is involved in all aspects of processing the clinical data, working with a range of computer applications, database systems.

JumpStart the Regulatory Review: Applying the Right Tools at the Right Time to the Right Audience Lilliam Rosario, Ph.D. Director Office of Computational.

Safety data collected during clinical trials is incorporated into the product’s approved label. Regulatory reviewers monitor products’ safety profiles.

Pharmacovigilance obligations of the Pharmaceutical companies in India

Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,

FDA Focus On Consumer Protection

ACCREDITED CONSULTANTS PVT LTD. (ACPL) WELCOMES YOU Your PHARMACOVIGILANCE PARTNER.

The New Drug Development Process (www. fda. gov/cder/handbook/develop

OFEV ® (nintedanib) safety Safety data INPULSIS ® -1 & -2 These slides are provided by Boehringer Ingelheim for medical to medical education only. Last.

Bernhard Breil, Benjamin Trinczek, Martin Dugas Dr. Bernhard Breil Portal of Medical Data Models – An open repository of Forms MedInfo 2013, Copenhagen.

FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.

Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.

Progression of New Drug: From Idea to Public Consumption Chris DeFarlo Writing in the HLTH Professions Unit 2 Prof. Edwards.

Methods We employ the UMLS Metathesaurus to annotate ICD-9 codes to MedDRA preferred terms (PTs) using the three-step process below. The mapping was applied.

Copyright © 2008 Delmar. All rights reserved. Chapter 4 Epidemiology and Public Health Nursing.

Event-Level Narrative

Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.

Safety and tolerability

FHIR Adverse Event Resource

European Society of Cardiology 2017 Clinical Trial Update I

The Information Professional’s Role in Product Safety

EudraVigilance.

Outline Immunity Artificial active immunization (vaccination)

To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

P.M. Tulkens,1 P. Arvis,2 F. Kruesmann,3

Adverse Event Reporting: Trials and Tribulations

Within Trial Decisions: Unblinding and Termination

Remote Monitoring of Adverse Events

Martha Carvour, MD, PhD March 2, 2017

The Role of Statistics in Clinical Trials

Intervista a Lucio Crinò

Remote Monitoring of Adverse Events

Clinical Trials in STS Shreyaskumar Patel, M.D.

An Endocrinology Clinic in Dyslipidemia

To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.

Epidemiology Venous Pathophysiology Etiology.

Creating PI-initiated Industry funded Clinical Trial EPD records:

Moving Evidence into Practice: Breast Cancer Highlights From Chicago

Quadrivalent Human Papillomavirus Vaccine (HPV4) Adverse Events

Beyond Statin Therapy.

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Long-term Data: INPULSIS®-ON

Statistical Programming

A: Kaplan-Meier estimate of time to first LLA

Unit 4 - Immunology and Public Health

Screening, Lipid Stabilization, and Placebo Run-in

Screening Epoch Disposition eCRF

Prioritizing Prevention of HPV-Related Disease

Model Enhanced Classification of Serious Adverse Events

Flow of Patients Through the Trial

Adverse Event Reporting _____________________________

Disclaimer These slides are as presented at the ESC Congress Amgen have made no amendments, apart from minor modification of language on slide.

Stakeholders for Communities of Care

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Research Techniques Made Simple: Teledermatology in Clinical Trials

All SAE* over time in 5 years.

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Algorithm for management of the patient with pain because of DSPN

Late-Breaking Data on LDL-C Reduction

Presentation transcript:

Adverse Event (AE) Coding Data mining and cleaning Medical literature screening and report writing Cleaning juggled Drug- AE data and converting to machine readable excel format Consolidated report comparing clinical trials of a diabetic drug MedDRA coding, Serious AE coding

Detailed annotated analysis and classification of Drug- AE- Disease relations Medical literature screening and analysis Risk/Benefit profile of a drug Comparison of safety and efficacy profile of newly approved drugs with existing drugs